Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF HR OFFICER | February 28, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 28, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 6,130 |
Ending reported balance
After 2025-03-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-02-28 · Tax withholding · Disposed 16,904 · Balance 27,380 Row 2 · 2025-03-03 · Sale · Disposed 5,677 · Balance 21,703 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 14,973 · Balance 6,730 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2025-03-03 · Sale · Disposed 600 · Balance 6,130 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 600 | $211.32 | $126,792.00 |
DisclosureSEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,130 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 14,973 | $210.66 | $3,154,212.18 |
DisclosureSEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,730 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 5,677 | $209.80 | $1,191,034.60 |
DisclosureSEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,703 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 16,904 | $205.02 | $3,465,658.08 |
DisclosureSEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,380 Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 22,210 | $114.36 Strike: $114.36 | $2,539,935.60 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · derivative · entry 8 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,210 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,829 | $203.63 | $983,329.27 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 7 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,284 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.55 to $203.68, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 13,073 | $202.92 | $2,652,773.16 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 6 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,113 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.55 to $203.46, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,308 | $201.97 | $870,086.76 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,186 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.55 to $202.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 22,210 | $114.36 | $2,539,935.60 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,526 | $203.64 | $310,754.64 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,284 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.58 to $203.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,781 | $202.93 | $970,208.33 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,810 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.58 to $203.56, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,400 | $202.06 | $282,884.00 |
DisclosureSEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,591 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.58 to $202.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 22,916 | $0.00 Strike: $192.86 | $0.00 |
DisclosureSEC source: 0001415889-25-004459 · form4-02182025_050209.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,916 Underlying: Common Stock · 22,916 shares Expires 2035-02-12 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,639 on February 13, 2026, 7,639 on February 13, 2027, and 7,638 on February 13, 2028. F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,639 on February 13, 2026, 7,639 on February 13, 2027, and 7,638 on February 13, 2028. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 6,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,991 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 5,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,993 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,201 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 17,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,823 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 45,700 | $61.36 Strike: $61.36 | $2,804,152.00 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · derivative · entry 6 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,700 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 20,127 | $177.71 | $3,576,769.17 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · nonDerivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,837 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.72 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 9,853 | $176.35 | $1,737,576.55 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,964 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.69, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 30,288 | $177.71 | $5,382,480.48 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,817 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023. F3 · price: he price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.77 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 15,412 | $176.40 | $2,718,676.80 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,105 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.72, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 45,700 | $61.36 | $2,804,152.00 |
DisclosureSEC source: 0001415889-24-006792 · form4-03052024_100336.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 23,847 | $178.99 | $4,268,374.53 |
DisclosureSEC source: 0001415889-24-006159 · form4-03012024_050311.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,817 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 28,998 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004428 · form4-02202024_100233.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,998 Underlying: Common Stock · 28,998 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,666 on February 15, 2025, 9,666 on February 15, 2026, and 9,666 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 5,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,664 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,872 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 8,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,492 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 32,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,934 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 16,746 | $153.62 | $2,572,520.52 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,837 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $154.13, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 27,395 | $153.08 | $4,193,582.77 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,583 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 35,111 | $154.28 | $5,416,925.08 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,978 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 21,944 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,944 Underlying: Common Stock · 21,944 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,089 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 8,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,709 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 11,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,149 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 51,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,172 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 42,370 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001415889-22-012547 · form4-12142022_101246.xml · derivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,370 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section16 under Rule 16b-3. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3,075 | $164.10 | $504,607.50 |
DisclosureSEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,837 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.08 to $164.18, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 39,295 | $163.39 | $6,420,410.05 |
DisclosureSEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,912 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.02 to $164.00, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 42,370 | $54.86 | $2,324,418.20 |
DisclosureSEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,627 | $149.09 | $391,654.96 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,837 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.905 to $149.46 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 14,424 | $148.59 | $2,143,195.81 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,464 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.91 to $148.90 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 9,381 | $147.52 | $1,383,917.95 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,888 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 21,027 | $149.54 | $3,144,377.58 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,269 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 35,026 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · derivative · entry 6 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,026 Underlying: Common Stock · 35,026 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 13,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,296 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,459 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,969 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,991 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.